Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early infant pertussis vaccination at birth versus standard start at 6 weeks
ACTRN12609000905268Phase 2Not yet recruiting
- Sponsor
- Peter McIntyre
- Start
- Nov 2009
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of GSK-251154 and Hepatitis B vaccine in pertussis (2 arms), sponsored by Peter McIntyre. Primary endpoint: Pertussis antibody immunogenicity. Planned start Nov 2009; status: not yet recruiting.
02
Drugs
GSK-251154Hepatitis B vaccine
03
Conditions
pertussis
Beyond the preview
Go deeper on ACTRN12609000905268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000905268.